Bibliometric mapping reveals a young field with sharp growth and uneven visibility
Evolutionary medicine has moved from a niche academic idea into a recognizable research domain, but its footprint remains uneven across databases, countries, and topic areas. A bibliometric analysis published in Evolution, Medicine, and Public Health examined the field’s output through the Web of Science Core Collection and found steady expansion since the 1990s, along with a research profile shaped heavily by review articles and a small number of high-producing countries.
Two search strategies framed the analysis. One captured the broader evolutionary medicine literature and identified 885 publications. The second focused on articles appearing in Evolution, Medicine, and Public Health itself and retrieved 358 publications. Using Bibliometrix and VOSviewer, the investigators assessed citation patterns, thematic clusters, and collaboration networks. The result is not merely a catalog of papers; it is a map of where the field has matured and where it still fails to show up in the record.
A striking feature of the corpus is the balance between intellectual momentum and institutional concentration. Publication volume has climbed steadily, but much of the citation influence comes from review articles rather than original clinical or mechanistic work. The dominant country contributors were the USA, the UK, and Germany, signaling a strong Western European and North American center of gravity. For a field that explicitly studies how biology, environment, and behavior interact across populations, that geographic concentration leaves important perspectives underrepresented.
Six keyword clusters define the current center of gravity
The keyword analysis separated the literature into six major clusters: drug resistance, infection, evolutionary mismatch, cancer, cognition, and mental health. Those categories show how evolutionary thinking has been applied to concrete biomedical problems, from pathogen adaptation to the mismatch between ancient human physiology and modern exposures. They also reflect a field that has spread across bench science, clinical inference, and population health without fully consolidating around one translational pipeline.
The prominence of drug resistance and infection is especially telling. Evolutionary biology offers a direct framework for understanding selective pressure, adaptive escape, and the persistence of resistant organisms under pharmacologic stress. In clinical terms, that makes the field useful where treatment strategies themselves can reshape the pathogen environment. Cancer and mental health occupy a different but equally important space: both involve complex interactions among biology, environment, and time, where evolutionary logic can help explain heterogeneity, tradeoffs, and persistence of maladaptive traits.
One sentence captures the most practical implication. Evolutionary medicine is already useful where selection pressure is visible at the bedside.
Underrepresented themes point to a translation gap
Despite the field’s growth, several areas remain thinly represented in the literature. Clinical translation, One Health, Planetary Health, and race-related issues appeared far less often than the dominant clusters. Those omissions matter because they mark the difference between a field that explains biological patterns and one that shapes real-world policy, clinical workflow, and population-level prevention.
The absence of stronger One Health and Planetary Health representation suggests that the literature has not fully connected human disease to animal, environmental, and ecological systems, even though those links are central to evolutionary reasoning. Likewise, limited attention to race-related issues leaves a gap in a domain that should be especially alert to how structural conditions, ancestry, and social context are often misread as biology. Evolutionary medicine can easily become abstract if it stays too close to theory and too far from the unequal exposures that drive illness in the clinic and in communities.
This is where bibliometric data become more than bookkeeping. They reveal what a field repeatedly chooses to study and what it leaves on the margins. The underrepresentation of clinically actionable and equity-focused topics suggests that evolutionary medicine still has room to mature into a broader translational discipline rather than a mostly conceptual one.
Indexing failures may be limiting the field’s reach
The most operationally important finding may be the least glamorous: standard database queries missed most EMPH articles. In practical terms, poor field identification in metadata makes evolutionary medicine harder to find, harder to cite, and harder to integrate into adjacent disciplines. A paper that cannot be reliably retrieved is easier to overlook in systematic reviews, grant planning, and clinical education.
That visibility problem has consequences beyond librarianship. Indexing shapes discovery, and discovery shapes collaboration. If journals and databases do not consistently label a publication as part of evolutionary medicine, the field loses coherence in the eyes of researchers who might otherwise enter it from oncology, infectious disease, psychiatry, or public health. The result is a research area that is active but partially hidden.
The authors’ findings imply a straightforward remedy: more consistent field labeling in publication metadata. Without that, even strong papers can disappear into adjacent categories and fail to reinforce the identity of the discipline they advance.
Collaboration remains concentrated while the field seeks broader reach
The collaboration network analysis reinforces the same message. Evolutionary medicine has generated useful international scholarship, but the network is still dominated by a relatively narrow set of countries and institutions. That pattern can accelerate progress when expertise is concentrated, yet it also risks narrowing the questions that receive attention. If the field wants to examine disease through an evolutionary lens at global scale, it will need more participation from regions where infectious disease burden, environmental stress, and health-system constraints differ sharply from those in the current citation centers.
Broader collaboration would also help the field test whether its concepts travel well across settings. Ideas about mismatch, selection, adaptation, and constraint may be biologically sound, but their public health value depends on how well they account for different populations, exposures, and systems of care. A discipline that studies evolution should be especially attentive to diversity in its own evidence base.
The analysis does not claim that evolutionary medicine lacks relevance. It shows the opposite: the field is growing, intellectually coherent, and already producing recognizable thematic clusters. What it has not yet solved is how to make itself easier to find, broader in scope, and more directly useful at the interface of medicine and public health.
A field with intellectual momentum but unfinished infrastructure
Bibliometric studies rarely change clinical practice on their own, but they can expose structural weaknesses that shape what gets studied next. Here, the signal is clear. Evolutionary medicine has established a publication base, a citation core, and several identifiable research themes. It has also left important territory underdeveloped, especially in translation, ecological framing, and equity-oriented inquiry.
Future work will need to do more than add papers to the pile. It will need better metadata, broader international collaboration, and closer engagement with the clinical and public health questions where evolutionary theory can be tested in real populations. Until that happens, the field will remain scientifically promising but only partially visible in the databases meant to organize it.